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Abstract: A new automated real-time PCR assay for the detection of rifampicin (RIF) and 
isoniazid (INH) resistance in Mycobacterium tuberculosis (MTB) was evaluated. A total of 163 
clinical samples (128 pulmonary and 35 extra-pulmonary) were processed using four PCR assay 
kits: Abbott RealTime MTB RIF/INH, Genotype MTBDRplus, Xpert/MTB RIF, and Anyplex 
MTB/MDR. The results of phenotypic drug-susceptibility testing using BACTECMGIT 960 
were used as reference. The sensitivity and specificity of the new Abbott RealTime MTB RIF/
INH assay in comparison with phenotypic testing was 96.3% (95%CI 87.32%–100%) for RIF 
and 100% (95%CI 99.3%–100%) for INH; the sensitivity was 78.8% (95%CI 66.8%–90.9%) and 
the specificity was 100% (95%CI 98.9%–100%). The Abbott RealTime MTB RIF/INH test could 
be a valid method for detecting the most common mutations in strains resistant to RIF and INH.
Keywords: Abbott RealTime MTB RIF/INH Resistance assay, M. tuberculosis, mutations
Introduction 
Drug-resistant tuberculosis (TB) continues to threaten global TB control and remains 
a major public health concern in many countries. Globally, an estimated 3.3% of new 
cases and 20% of previously treated cases have multidrug-resistant TB (MDR-TB). 
The World Health Organization’s (WHO’s) End TB Strategy calls for the early diag-
nosis of TB and universal drug-susceptibility testing (DST), highlighting the critical 
role of laboratories in the post-2015 era in rapidly and accurately detecting TB and 
drug resistance.1,2 Surveillance of drug resistance in TB over the past 2 decades has 
informed and guided the response to the epidemic. Molecular tests for detecting drug 
resistance to rifampicin (RIF) alone or in combination with resistance to isoniazid 
(INH) have been recommended for use by WHO.3
The latest WHO data offer an estimated 10.4 million new (incident) TB cases 
worldwide, of which 1.2 million (11%) were people living with HIV, 480,000 new 
cases of MDR-TB, and ~190,000 deaths from MDR-TB. On average, an estimated 
9.7% of people with MDR-TB have extensive drug resistant-TB. It is estimated that 
up to 50 million people may be infected with drug-resistant TB.2 
The WHO European region is the area most affected by MDR-TB in the entire 
world. Of the ten countries in the world with the highest burden of MDR-TB, nine are 
Correspondence: Manuel Casal
Mycobacteria Reference Center, 
Department of Microbiology, Faculty of 
Medicine, University of Córdoba, Avda 
Menéndez Pidal s/n, 14004 Córdoba, 
Spain
Tel +34 957 21 83 24 
Email mi1carom@uco.es 
Journal name: Infection and Drug Resistance 
Article Designation: ORIGINAL RESEARCH
Year: 2017
Volume: 10
Running head verso: Ruiz et al




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





in the European region, with ~190,000 deaths from MDR-TB 
per year. In 2015, estimated  percentages of MDR among new 
and previously treated TB cases in this region were 16% and 
48%, respectively.4
There was a US$2 billion funding shortfall for the imple-
mentation of TB treatment in 2016 and over US$1 billion for 
TB research. In industrialized countries, TB treatment costs 
approximately US$250,000 for patients with drug-resistant TB. 
MDR-TB is currently responsible for 150,000 deaths per year. 
WHO reports that only 7% of MDR-TB cases are diagnosed.1,2 
Until recently, systems for detecting resistance using 
solid media were slow and laborious. The development of a 
modern liquid-medium, non-radiometric system (BactecTM 
MGITTM 960 System; BD, Franklin Lakes, NJ, USA) has done 
much to speed up the detection process, allowing the testing 
of any patient requiring it.5
Recent innovations in molecular tests are facilitating the 
shift from periodic surveys to routine surveillance. Rapid 
molecular tests such as Genotype MTBDRplus (Hain Life-
science, Nehren, Germany),6 Xpert/MTB RIF assay (Cepheid 
AB, Bromma, Sweden),7 and Anyplex MTB/MDR (Seegene 
Technologies, Concord, CA, USA)8 provide results much 
faster than conventional methods, do not require sophisticated 
laboratory infrastructure, and decrease cost.
WHO indicates the approval of use of these molecular 
tests for rapid detection of MDR-TB should be decided by the 
ministries of health of each country in the context of national 
plans for the proper management of patients with MDR-TB. 
These tests must be adequately validated for use in sputum 
smear positive for Mycobacterium tuberculosis (MTB). 
The use of commercial methods, experienced centers, and 
adequate funding are recommended. Therefore, phenotypic 
tests are still necessary. 
The Abbott RealTime MTB RIF/INH Resistance assay 
(Abbott Laboratories, Abbott Park, IL, USA) is a new com-
panion assay to the Abbott RealTime MTB,9 for the qualita-
tive detection of RIF and INH resistance in MTB-positive 
respiratory samples via a fully automated process. 
In this study, we have evaluated the new automated Abbott 
RealTime MTB RIF/INH Resistance assay using pulmonary 
and extra-pulmonary clinical samples, in a comparison with 
three other marketed PCR test kits, using a standard culture 
phenotypic system as the reference method. 
Materials and methods
A total of 163 frozen decontaminated clinical samples 
(128 pulmonary and 35 extra-pulmonary) were processed 
 (Figure 1). The sources of the samples were: 103 sputum, 
25 bronchial aspirate, 21 biopsy, one fistula of chest wall, 
one cervical fistula, three gastric aspirate, and nine exudates. 
Under the directive of the Official Gazette of the Govern-
ment of Spain, Real Decreto 1716/2011, no ethics approval 
is required for the use of anonymized clinical samples which 
constitute customary professional diagnostic procedures.
All samples were processed with the new automated 
Abbott RealTime MTB RIF/INH Resistance assay. To inac-
tivate MTB, inactivation reagent was added to the samples 
(in a 1:3 ratio) and they were incubated for 1 hour. DNA 
extraction, amplification, and detection were performed 
automatically with the instrument Abbott m2000rt, which 
had been set up with the appropriate reagents according 
to manufacturer’s instructions. After inactivation, samples 
were inoculated on a 24-well plate – 22 samples and two 
controls, positive and negative. The extraction and prepara-
tion of DNA was performed with the lysing reagent and 
Figure 1 Flow diagram for Abbott RealTime MTB RIF/INH evaluation.
Abbreviations: MTB, Mycobacterium tuberculosis; RIF, rifampicin; INH, isoniazid; 
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New automated resistance assay in M. tuberculosis
magnetic microparticles. When identification results were 
“MTB detected”, the detection of resistance was considered. 
Then, the amplification mixture was prepared and added to 
the Abbott system, and the amplification was made. Targets 
were rpoB (RIF resistance), katG and inhA promoter regions 
(resistance to INH). The detection was determined by the 
joint interpretation of 12 signals from different probes: eight 
wild-type rpoB probes and probes at katG e inhA.10
In this study, 131 cases of MTB were identified with the 
RT MTB, and the resistance to RIF and INH was determined 
in 99 samples, with Abbott RealTime MTB INH/RIF (RT 
MTB INH/RIF) (23 samples were identified as non-TB 
mycobacteria and nine samples with low level of detection 
[LOD] were not considered in this study). MTB resistance to 
RIF was detected with eight rpoB wild-type probes and eight 
mutation probes; MTB resistance to INH was detected with 
two wild-type probes and two mutation probes, one wild-type 
probe with mutation probes in inhA and one wild-probe with 
mutation  in katG. All samples had been previously identified 
with Genotype CM/AS (Hain Lifescience, Nehren, Ger-
many). The results previously obtained of phenotypic DST 
using BACTECMGIT 960 were used for reference. When 
there were discrepancies between results from the molecular 
test Abbott RealTime MTB INH/RIF (RT MTB INH/RIF) 
and phenotypic DST, the following tests were performed, 
according to the manufacturer’s instructions, to confirm the 
results: Genotype MTBDR plus, Xpert/MTB RIF assay, and 
Anyplex MTB/MDR.
Statistical analysis
Statistical analyses were carried out using EpiData version 
3.1 software (EpiData Association, Copenhagen, Denmark) 
to calculate sensitivity, specificity, negative and positive 
predictive values, and kappa index of concordance between 
techniques. We determined 95% CIs.
Results
Of the 163 frozen clinical samples processed with the 
Abbott RealTime MTB, in nine (seven pulmonary and two 
extra-pulmonary) samples, extracted DNA was detected as 
“low”. One hundred and thirty-one samples were  identified 
as MTB and 23 samples were identified as non-MTB. All 
samples were processed with the Genotype Mycobacteria 
CM/AS (131 MTB and 23 different non-TB mycobacteria).
Of the 131 MTB samples, 99 were tested for resistance, 
using RealTime MTB INH/RIF (RT MTB INH/RIF). The 
results were compared with the phenotypic test (Table 1). Of 
the 72 samples that were phenotypically susceptible to RIF, no 
rpoB mutation was detected by Abbott RealTime MTB RIF/
INH, and of the 27 samples that were resistant to RIF, Abbott 
RealTime MTB INH/RIF detected resistance mutations in 26 
of them. Only in one phenotypically RIF resistant sample was 
the mutation not detected. With the Genotype MTBDRplus, 
Xpert/MTB RIF assay, and Anyplex MTB/MDR, the muta-
tion was detected. For the RIF resistance mutation, the Abbott 
RealTime MTB RIF/INH test demonstrated 96.3% (95%CI 
87.32%–100%) sensitivity and 100% (95%CI 99.3%–100%) 
specificity. The kappa coefficient between the Abbott Real-
Time MTB RIF/INH Resistance assay and the indirect DST 
results for RIF was 0.97 (95%CI 0.92–1), classified according 
to the Landis and Koch scale as “almost perfect agreement”. 
Of the 47 samples that were phenotypically susceptible to 
INH, no mutations in InhA or Kat G were detected. Of the 
52 phenotypically INH  resistant samples, eleven showed no 
mutations with any of the molecular methods tested. For 
INH, the Abbott RealTime MTB RIF/INH test displayed 
78.8% (95%CI 66.8%–90.9%) sensitivity and 100% (95%CI 
98.9%–100%) specificity. The kappa coefficient between the 
Abbott RealTime MTB RIF/INH Resistance assay and the 
indirect DST results was 0.78 (95%CI 0.66–0.90), “substantial 
agreement” according to the Landis and Koch scale.




Resistant Susceptible Resistant Susceptible
Abbott
RealTime MTB RIF/INH
Resistant 26 (96.3%) 0 (0%) 41 (78.8%) 0 (0%)
Susceptible 1 (3.7%) 72 (100%) 11 (21.2%) 47 (100%)
Sensitivity: 96.3% (95%CI 87.3%–100%) 
Specificity: 100% (95%CI 99.3%–100%) 
PPV: 100% (95%CI 99.1%–100%) vs 100% (95%CI 
98.3%–100%)
NPV: 98.6% (95%CI 95.3%–100%)
Sensitivity: 78.8% (95%CI 66.8%–90.9%) 
Specificity: 100% (95%CI 98.9%–100%) 
PPV: 100% (95%CI 98.8–100%) 
NPV: 81.0% (95%CI 70.1%–92.0%)
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Twelve samples with discrepancies were compared with 
other genotypic tests (Table 2). In the phenotypically RIF 
resistant sample, the mutation was not detected with Abbott 
RealTime MTB INH/RIF (RT MTB INH/RIF); the other 
genotypic test detected this mutation (H526D).
For INH, eleven samples were phenotypically resistant; 
no mutations were detected with any of the molecular meth-
ods tested.
Discussion 
The Abbott RealTime MTB RIF/INH is a novel, fully auto-
mated real-time PCR system for diagnosis of MTB and 
resistance to RIF and INH in clinical respiratory samples. 
The aim of this study was to evaluate this method using 
pulmonary and extra-pulmonary samples compared with 
three other commercial PCR test kits. The results obtained 
using Abbott RealTime MTB RIF/INH corresponded with 
those obtained using the three molecular techniques and with 
phenotypic DST, except in 12 samples. Only one of these 
samples was discordant for RIF, which is possibly due to the 
use of frozen samples,11 and the eleven remaining samples 
were discordant for INH, due to other genes involved in 
resistance to this drug. The sensitivity for RIF was 96.3%, 
and the sensitivity for INH was 78.8%.
The sensitivity and specificity results of Abbott RealTime 
MTB RIF/INH have been published in recent papers. Kostera 
et al10 performed a study to evaluate this test in pulmonary 
samples in comparison with phenotypic results, demonstrat-
ing a sensitivity to RIF of 94.8%. There were five samples 
phenotypically resistant which were not detected by Abbott 
RealTime MTB RIF/INH. When sequencing was performed, 
four of them were found to be wild type, and mutation was 
detected in one sample. The specificity for RIF was 100%. 
Comparing these results with Genexpert, a sensitivity of 
95.8% and a specificity of 100% were detected. For INH, 
the sensitivity was 88.3% and the specificity was 93.3%. 
Eleven samples were resistant according to DST and were not 
detected by Abbott RealTime MTB RIF/INH. The sequencing 
results showed that, in only one sample, the Abbott RealTime 
MTB RIF/INH assay did not detect the mutation (S315T1). 
Thus, Abbott RealTime MTB RIF/INH results presented 
statistically equivalent sensitivity and specificity as compared 
to Genexpert and Genotype MTBDRplus.10
A study conducted by Hoffman-Thiel et al11 evaluated 
Abbott RealTime MTB RIF/INH in respiratory and extra-
pulmonary samples. Comparing the results with phenotypic 
testing (DST) and Genotype MTBDRplus, a concordance of 
100% was obtained for RIF, and Abbott RealTime MTB RIF/
INH failed in only one sample. A mutation to INH in katG 
(S315t), which was detected by Genotype MTBDRplus and 
phenotypic testing, showed high sensitivity with paucibacil-
lary samples.11
A recent study was carried out in respiratory samples 
with Abbott RealTime MTB RIF/INH in China, comparing 
the resistance results with the phenotypic test MGIT 960 
SIRE and Sanger sequencing. For RIF, 100% concordance 
was obtained using genotypic testing, and 78.2% using 
phenotypic testing.12
TB and HIV coinfection is a problem in some countries 
such as South Africa, where there is a high incidence. An 
Abbott RealTime MTB RIF/INH study has been carried 
out in Johannesburg and results have been compared with 
 Genexpert MTB/RF. Of the 206 individuals studied, 73% 
were HIV positive and better results were obtained compared 
to Genexpert. The most important disadvantage in the study 
was the high percentage (33%) of samples with a low LOD.13
Like the previously published studies, our research had its 
limitations. Due to the use of frozen samples from our collec-
tion to carry out our study, results could have been affected. In 
this case, Abbott RealTime MTB RIF/INH did not detect the 




Resistant Susceptible Resistant Susceptible
Abbott
RealTime MTB RIF/INH
Resistant 0 0 0 0
Susceptible 1 0 11 0
Genotype MTBDRplus Resistant 1 0 0 0 
Susceptible 0 0 11 0 
Anyplex MTB/MDR Resistant 1 0 0 0 
Susceptible 0 0 11 
Xpert/MTB RIF Resistant 1 0 ND ND 
Susceptible 0 0 ND ND
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resistance to RIF in a sample, while the other methods did detect 
it. This may be because they were carried out with samples that 
were not fresh; however, there was only one discordant sample.
The main advantage of this method is that the whole 
sample preparation, identification, and mutation detection 
process is totally automatic and allows automatic processing 
of a large number of samples. Its sensitivity and specificity 
is comparable to other tests.
Conclusion
The Abbott RealTime MTB RIF/INH test could be a valid 
method for detecting the most common mutations in strains 
resistant to RIF and INH. Although the test is designed 
for respiratory samples, based on our results with positive 
extra-pulmonary clinical samples, it seemed to have cor-
rectly detected the mutations of resistance, although further 
research is required to confirm these findings. Furthermore, 
the whole process is automated; it is no more expensive 
than any of the other methods and has an advantage over 
Genexpert – the detection of INH.
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